Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infection rates with different routes of alimentation.

Comment by InpharmD Researcher

In oncology patients receiving TPN/HPN, reported bloodstream infection incidence varies widely between stides. Several studies associate PN with increased catheter-related infection risk, but a hematologic malignancy study found no CLABSI association after adjustment. Among catheter routes, HPN data show potentially lower CRBSI with PICCs and ports than Hohn/tunneled catheters, but no direct enteral-versus-parenteral infection-rate comparisons were identified.
Literature Review

A search of the published medical literature revealed 7 studies investigating the researchable question:

Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infection rates with different routes of alimentation.

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→



Please see Tables 1-7 for your response.


Incidence of catheter-related infection in cancer patients receiving parenteral nutrition
Design

Retrospective cohort study

N= 26,377

Objective To estimate the effect of parenteral nutrition (PN) on catheter-related infection (CRI) in cancer patients after catheter placement
Study Groups

Gastric cancer (n= 5300)

Pancreatic cancer (n= 5975)

Lung cancer (n= 15,102)

Inclusion Criteria Patients aged ≥18 years with gastric, pancreatic, or lung cancer and central venous catheter insertion between 2012 and 2016
Exclusion Criteria Patients with a history of any type of cancer within 2 years before enrollment
Methods

Retrospective analysis of the French National Health Data System. Incidence rates of CRI were calculated, and Poisson regression was used to evaluate potential confounders. Incidence rate ratio (IRR) was estimated to assess the effect of PN on infection occurrence.

Duration January 2012 to December 2016
Outcome Measures

Primary: Incidence of catheter-related infection (CRI)

Secondary: Incidence rate ratio (IRR) of CRI with PN vs. without PN

Baseline Characteristics   Gastric cancer (n= 5300) Pancreatic cancer (n= 5975) Lung cancer (n= 15,102)
Age at cancer diagnosis, mean [SD] 69.16 [13.44] 68.17 [11.89] 64.36 [10.71]
Male, n (%) 3377 (63.72%) 3284 (54.96%) 10897 (72.16%)
Presence of malnutrition, n (%) 2532 (47.77%) 2846 (47.63%) 4903 (32.47%)
Metastasis, n (%) 2977 (56.17%) 3261 (54.58%) 9850 (65.22%)
Chemotherapy at baseline, n (%) 2072 (39.09%) 2391 (40.02%) 7021 (46.49%)
Results   Gastric cancer (n= 5300) Pancreatic cancer (n= 5975) Lung cancer (n= 15,102)
Incidence of CRI, n (%) 1684 (31.77%) 1897 (31.75%) 3380 (22.38%)
Incidence of CRI with PN, n (%) 747 (34.84%) 714 (38.89%) 597 (23.64%)
Incidence of CRI without PN, n (%) 937 (29.69%) 1183 (28.58%) 2783 (22.13%)
Adverse Events Not specifically reported
Study Author Conclusions

PN is an independent risk factor for CRI in cancer patients, but the risk is smaller than previously reported. Close monitoring is required for patients receiving PN.

Critique

The study benefits from a large sample size and comprehensive national data, enhancing its reliability. However, limitations include potential misclassification due to the nature of claims data, lack of detailed clinical data, and inability to validate CRI definitions from claims data. The retrospective design may also introduce biases.

 

Table 1 References:
[1] Taieb J, Pellerin O, de Pouvourville G, et al. Incidence of catheter-related infection in cancer patients receiving parenteral nutrition: A retrospective cohort study of French administrative claims data. Medicine (Baltimore). 2025;104(23):e42704. doi:10.1097/MD.0000000000042704
Incidence of and factors associated with catheter-related bloodstream infection in patients with advanced solid tumors on home parenteral nutrition managed using a standardized catheter care protocol
Design

Retrospective cohort study

N= 335

Objective To evaluate the incidence of and factors associated with catheter-related bloodstream infections (CRBSIs) in cancer patients undergoing home parenteral nutrition (HPN) managed using a standardized catheter care protocol
Study Groups All patients (n= 335)
Inclusion Criteria Patients with advanced solid tumors receiving home parenteral nutrition between January 2012 and July 2015 at Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center
Exclusion Criteria No exclusions at any stage
Methods

Retrospective analysis of 335 cancer patients receiving HPN. VADs used were PICCs, subcutaneous implanted ports, or TCCs. CRBSI incidence was calculated as events per 1000 HPN days. Univariate Poisson regression analyses were used to determine variables associated with CRBSIs.

Duration January 2012 to July 2015
Outcome Measures

Primary: Incidence of CRBSI per 1000 HPN days

Baseline Characteristics   All patients (n= 335)
Gender - Female 193 (57.6%)
Gender - Male 142 (42.4%)
Mean Age, years 53.7
Cancer site - Colorectal 71 (21.2%)
Cancer site - Pancreas 59 (17.6%)
Cancer site - Ovary 35 (10.4%)
Cancer site - Stomach 29 (8.7%)
SGA - Well-nourished 62 (18.5%)
SGA - Moderately Malnourished 175 (52.2%)
SGA - Severely Malnourished 98 (29.3%)
Results   Port PICC TCC Total
Number of CRBSI 8 7 1 16
Number of CRBSI/1000 HPN Days (95% CI) 0.47 (0.20–0.93) 0.61 (0.25–1.3) 0.93 (0.02–5.2) 0.54 (0.32–0.86)
Adverse Events Not specifically reported
Study Author Conclusions We found a low rate of CRBSI following a standardized catheter maintenance protocol in a high-risk oncology population undergoing HPN.
Critique

The study's strengths include a large sample size and a focus on a high-risk population with standardized catheter care protocols. However, its retrospective nature and lack of data on all potential confounding variables may limit the findings. Additionally, the study was conducted at a single institution, which may affect generalizability.

 

Table 2 References:
[2] Vashi PG, Virginkar N, Popiel B, Edwin P, Gupta D. Incidence of and factors associated with catheter-related bloodstream infection in patients with advanced solid tumors on home parenteral nutrition managed using a standardized catheter care protocol. BMC Infect Dis. 2017;17(1):372. Published 2017 May 30. doi:10.1186/s12879-017-2469-7
Central Line–Associated Bloodstream Infection in Patients With Hematologic Malignancy Receiving Parenteral Nutrition
Design

Single-center, retrospective analysis

N= 1,617

Objective To evaluate risk of central line–associated bloodstream infection (CLABSI) in patients with hematologic malignancy receiving parenteral nutrition with modern infection prevention practices
Study Groups Hospital Encounters Including PN Administration (n= 334) Hospital Encounters Not Including PN Administration (n= 3,295)
Inclusion Criteria Patients with central venous catheters admitted and discharged from the hematologic malignancy services of the Hospital of the University of Pennsylvania between April 1, 2017, and June 30, 2019
Exclusion Criteria Not specified
Methods

Retrospective analysis of patients with hematologic malignancies, evaluating the association of PN administration with CLABSI risk. Data included demographic characteristics, CVC days, days of neutropenia, and PN administration. Logistic regression was used to assess the association of PN with CLABSI, adjusting for cancer type, neutropenia, and catheter days.

Duration April 1, 2017, to June 30, 2019
Outcome Measures

Primary: Incidence of CLABSI

Secondary: Proportion of MBI-CLABSI

Baseline Characteristics   Hospital Encounters Including PN Administration (n= 334) Hospital Encounters Not Including PN Administration (n= 3,295)  
Age, years, median [IQR] 59 [51- 66] 61 [50- 68]  
Sex - Female 180 (54%) 1,416 (43%)  
Sex - Male 154 (46%) 1,879 (57%)  
Type of cancer - Leukemia 129 (39%) 1,426 (43%)  
Type of cancer - Lymphoma 56 (17%) 1,143 (35%)  
Type of cancer - Myeloma and other plasma cell disorders 114 (34%) 537 (16%)  
Type of cancer - Others 35 (10%) 189 (6%)  
Catheter days, median [IQR] 23 [16- 33] 7 [5- 17]  
Neutropenic days, median [IQR] 5 [0- 10] 0 [0- 5]  
Results CLABSI Sub-type Hospital Encounters Including PN Administration (n= 15) Hospital Encounters Not Including PN Administration (n= 151) p-Value
MBI-CLABSI 11 (73%) 106 (70%) 0.800
Non–MBI-CLABSI 4 (27%) 45 (30%)  
Adverse Events Not specified
Study Author Conclusions

PN administration and duration of PN exposure were not associated with risk of CLABSI in patients with hematologic malignancy using modern infection prevention practices. The high proportion of MBI-CLABSI emphasizes the association of gut permeability with infection risk.

Critique

The study's strengths include a large sample size and consecutive admissions. However, its retrospective design limits the ability to establish causality. Differences in baseline characteristics and events during hospitalization between groups may not have been fully accounted for, and variability in infection control practices among centers limits generalizability.

 

Table 3 References:
[3] Lazarow H, Compher C, Ziegler MJ, Gilmar C, Kucharczuk CR, Landsburg DJ. Central Line-Associated Bloodstream Infection in Patients With Hematologic Malignancy Receiving Parenteral Nutrition. JCO Oncol Pract. 2023;19(8):571-576. doi:10.1200/OP.22.00823
Total Parenteral Nutrition Is a Major Risk Factor for Central Venous Catheter-Related Bloodstream Infection in Colorectal Cancer Patients Receiving Postoperative Chemotherapy
Design

Retrospective study

N= 109

Objective To clarify the risk factors for central venous catheter-related bloodstream infection (CVCR-BSI) in patients receiving chemotherapy after surgery for colorectal cancer (CRC)
Study Groups

CVCR-BSI negative (n= 536)

CVCR-BSI positive (n= 6)

Inclusion Criteria Patients who had undergone CVC insertions for postoperative chemotherapy after surgery for advanced CRC between January 2005 and August 2007
Exclusion Criteria Not explicitly stated
Methods Retrospective review of 109 patients who had undergone CVC insertions for postoperative chemotherapy. Catheters were inserted using the single-puncture method with maximal barrier precautions. Blood culture positivity was used to determine CVCR-BSI presence
Duration January 2005 to August 2007
Outcome Measures Primary: Development of CVCR-BSI
Baseline Characteristics   CVCR-BSI negative (n = 536) CVCR-BSI positive (n = 6) p-Value
Age, years 63.3 ± 0.4 58.5 ± 1.9 0.2080
Length of inserted catheter, cm 16.9 ± 0.3 21.3 ± 6.7 0.1461
Catheterization duration, days 10.2 ± 0.4 16.2 ± 4.7 0.0978
Results   CVCR-BSI negative (n = 536) CVCR-BSI positive (n = 6) p-Value
Administration of TPN (yes/no) 39/497 3/3 <0.0001
Adverse Events Not explicitly stated
Study Author Conclusions

TPN is a major risk factor for CVCR-BSI in CRC patients receiving postoperative chemotherapy.

Critique

The study identifies TPN as a significant risk factor for CVCR-BSI, providing valuable insights for clinical practice. However, the retrospective design and small sample size of CVCR-BSI positive cases may limit the generalizability of the findings. Additionally, the study does not explore other potential risk factors in depth, such as patient comorbidities or variations in catheter care practices.

 

Table 4 References:
[4] Ishizuka M, Nagata H, Takagi K, Kubota K. Total parenteral nutrition is a major risk factor for central venous catheter-related bloodstream infection in colorectal cancer patients receiving postoperative chemotherapy. Eur Surg Res. 2008;41(4):341-345. doi:10.1159/000160181
Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction
Design

Retrospective, single-center cohort study

N= 68

Objective To review individual patient outcomes on parenteral nutrition in the setting of advanced cancer with a diagnosis of malignant bowel obstruction and identify clinical and laboratory markers predictive of short- and long-term survival
Study Groups All patients (n= 68)
Inclusion Criteria Patients 18 years or older with a diagnosis of advanced cancer and an admission for malignant bowel obstruction between 1/1/2013 and 4/1/2021, discharged on parenteral nutrition
Exclusion Criteria Age <18, admissions for alternative diagnoses not for MBO, admissions requiring only perioperative PN, discharge without PN, receiving care at another institution resulting in untraceable clinical data
Methods

Retrospective review of patients receiving PN for inoperable MBO. Data collected included cancer characteristics, PN characteristics, ECOG performance status, prior admissions, readmissions, hospice enrollment, and laboratory values. Complications of MBO and PN utilization were also recorded.

Duration January 2013 to April 2021
Outcome Measures

Primary: Patient survival on PN

Secondary: PN-related complications, number of hospital readmissions following PN initiation

Baseline Characteristics   All patients (n= 68)
Age, years, median (IQR) 57.5 (50.3–66)
Male sex, n (%) 30 (44.1%)
White race, n (%) 42 (63.6%)
Weight at PN initiation, kg, median (IQR) 66 (55.8–76.3)
Six-month weight loss before PN initiation, %, median (IQR) 8.4 (4.1–17.6)
Body mass index, median (IQR) 22.6 (20–26.2)
Cancer features - Colorectal, n (%) 15 (22.1%)
Cancer features - Gastric/gastroesophageal, n (%) 8 (11.8%)
Cancer features - Gynecologic, n (%) 7 (10.3%)
Cancer features - Appendiceal, n (%) 24 (35.3%)
Cancer features - Other, n (%) 14 (20.6%)
ECOG, n (%) - 0 6 (9.2%)
ECOG, n (%) - 1 29 (44.6%)
ECOG, n (%) - 2 16 (24.6%)
ECOG, n (%) - 3 14 (21.5%)
ECOG, n (%) - 4 1 (1.5%)
Laboratory values at PN initiation - Hemoglobin, g/dL, median (IQR) 9.8 (8.8–11.7)
Laboratory values at PN initiation - WBC, cells/103uL, median (IQR) 7.8 (5.2–10.8)
Laboratory values at PN initiation - Albumin, g/dL, median (IQR) 3.1 (2.8–3.5)
Laboratory values at PN initiation - CRP, mg/dL, median (IQR) 32 (9–76)
Nutrition Risk Index, median (IQR) 80.8 (73.3–85.4)
Treatment features - History of exposure to chemotherapy, n (%) 68 (100%)
Treatment features - Prior history of radiation therapy, n (%) 3 (4.4%)
Treatment features - Prior surgical resection, n (%) 45 (66.2%)
Treatment features - History of HIPEC, n (%) 17 (25%)
Treatment features - Chemotherapy administered after MBO, n (%) 43 (66.2%)
Results   All patients (n= 68)
Median survival, days (IQR) 142 (63.3–239.5)
Median number of hospital readmissions (range) 2 (0–10)
Median days spent in hospital after starting PN (range) 29 (0–105)
Patients with CRBSI, n (%) 18 (26.5%)
Appendiceal cancer as predictive marker of improved survival (HR, 95% CI, p-value) 0.53, 0.29–0.92, 0.023
Adverse Events Catheter-related bloodstream infection (CRBSI) occurred in 26.5% of patients. Other complications included abdominal pain (75%), sepsis (36.8%), deep vein thrombosis (17.6%), ascites (33.8%), and pleural effusion (32.4%)
Study Author Conclusions

The use of parenteral nutrition in end-of-life cancer care requires improvement. Recognizing patient outcomes and experiences with PN is essential for physicians and patients.

Critique

The study provides valuable insights into the outcomes of PN in advanced cancer patients with MBO, highlighting appendiceal cancer as a predictor of improved survival. However, the retrospective design and single-center setting may limit the generalizability of the findings. The study's reliance on medical records could introduce biases, and the sample size may not capture the full spectrum of PN outcomes across diverse cancer subtypes. Further prospective studies are needed to validate these findings and explore the broader applicability of PN in this patient population.

Table 5 References:
[5] Velasquez DA, Dhiman A, Brottman C, et al. Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction. Support Care Cancer. 2024;32(3):206. Published 2024 Mar 4. doi:10.1007/s00520-024-08403-8
Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients
Design

Observational cohort study

N= 425

Objective To estimate the effect of parenteral nutrition on central venous catheter-related bloodstream infection (CVC-RBSI) in digestive cancer patients who underwent chemotherapy
Study Groups

Parenteral nutrition (n= 113)

Without parenteral nutrition (n= 312)

Inclusion Criteria Diagnosis of digestive cancer, age ≥18 years, and central venous catheter insertion for chemotherapy
Exclusion Criteria Not specified
Methods

Data were collected prospectively. A logistic regression model was used to calculate a propensity score for receiving parenteral nutrition. Kaplan-Meier survival and Cox regression models were used to estimate the effect of parenteral nutrition on CVC-RBSI after adjustment for the propensity score.

Duration March 1, 2007 to February 1, 2012
Outcome Measures Primary: Risk of CVC-RBSI
Baseline Characteristics   Chemotherapy and PN (n= 113) Chemotherapy (n= 312)
Age, mean ± SD 62.9 ± 13.1 63.2 ± 13.1
Male 80 (70.8%) 180 (57.7%)
BMI 21.75 ± 4.44 24.04 ± 4.26
% weight loss 13.92 ± 7.53 9.38 ± 7.47
Long-term corticotherapy 6 (5.3%) 3 (0.96%)
WHO performance status 0 33 (29.2%) 156 (50.0%)
Primary location of cancer - Colorectal 21 (18.6%) 119 (38.1%)
Primary location of cancer - Stomach 21 (18.6%) 31 (9.9%)
Primary location of cancer - Pancreas 36 (31.9%) 77 (24.7%)
Results   Chemotherapy and PN Chemotherapy p-Value
CVC-RBSI occurrence Higher Lower <0.001
Adverse Events Not specified
Study Author Conclusions Parenteral nutrition was confirmed as an independent risk factor for CVC-RBSI in digestive cancer patients. The study suggests that PN should not be systematically given to patients with malnutrition or difficulty eating without careful consideration.
Critique The study effectively used propensity score analysis to address confounding factors, enhancing the reliability of the findings. However, the observational design limits causal inference, and residual confounders not included in the propensity score estimation may still affect the results. Additionally, the study was monocentric, which may limit generalizability.

 

Table 6 References:
[6] Tour A, Chambrier C, Vanhems P, Lombard-Bohas C, Souquet JC, Ecochard R. Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients. Clin Nutr. 2013;32(6):1050-1054. doi:10.1016/j.clnu.2012.12.006
Catheter-Related Complications in Cancer Patients on Home Parenteral Nutrition: A Prospective Study of Over 51,000 Catheter Days
Design

Prospective, observational, single-center study

N= 254

Objective To investigate the actual incidence of VAD-related complications in cancer patients on HPN
Study Groups All patients (n= 254)
Inclusion Criteria All adult cancer patients who were candidates for HPN and had a medium- or long-term central VAD inserted during the study period
Exclusion Criteria None specified
Methods Four types of VADs were used: PICCs, Hohn catheters, tunneled Groshong catheters, and ports. VADs were inserted with maximal barrier precautions and skin antisepsis with 2% chlorhexidine. Ultrasound-guided venipuncture was used for PICCs. Follow-up included regular telephone interviews, in-hospital examinations, and home visits. CRBSIs were treated with systemic antibiotics and/or antibiotic lock therapy
Duration June 1, 2008, through November 30, 2009
Outcome Measures

Primary: Incidence of catheter-related bloodstream infections (CRBSIs)

Secondary: Incidence of mechanical complications, VAD-related venous thrombosis

Baseline Characteristics   All patients (n= 254)
Female sex, No. (%) 123 (48%)
Age, y, median (range) 67 (29–85)
BMI, median (range) 20.3 (13.3–34.2)
Weight loss, %, median (range) 11.4 (0–34.9)
Tumor site - Stomach 63 (25%)
Tumor site - Pancreas/biliary system 48 (19%)
Tumor site - Colon/rectum 38 (15%)
Stage IV, No. (%) 199 (78%)
Karnofsky PS, median (range) 60 (50–90)
Results   PICC Hohn Tunneled Port Total
CRBSI, No./1000 catheter-days 0 0.87 0.64 0.19 0.35
Mechanical complications, No./1000 catheter-days 0.78 1.83 0.77 0.32 0.80
Venous thrombosis, No. (%) 0 3 (2.8%) 0 0 3 (1%)
Adverse Events Infectious complications were low, with CRBSIs at 0.35/1000 catheter-days. Mechanical complications were uncommon at 0.8/1000 catheter-days. VAD-related venous thrombosis was rare at 0.06/1000 catheter-days
Study Author Conclusions HPN can be safely provided for cancer patients with a low incidence of CRCs. Different VADs have varying complication rates, and proper choice and insertion technique are crucial in reducing CRCs.
Critique The study's strengths include its prospective design and large sample size. However, being a single-center study, the findings may not be generalizable. Differences in PN formulas or cancer treatments among VAD types might have influenced outcomes. The lack of randomization is a limitation.

 

Table 7 References:
[7] Cotogni P, Pittiruti M, Barbero C, Monge T, Palmo A, Boggio Bertinet D. Catheter-related complications in cancer patients on home parenteral nutrition: a prospective study of over 51,000 catheter days. JPEN J Parenter Enteral Nutr. 2013;37(3):375-383. doi:10.1177/0148607112460552